ANI Pharmaceuticals, Inc., a Baudette, Minnesota-based specialty pharmaceutical company, has signed an exclusive distribution and supply agreement with Aspen Global Incorporated for hydroxyprogesterone caproate (HPC) injection USP 250 mg/mL in 5-mL vials. Aspen will be responsible for supplying the finished goods, and ANI Pharmaceuticals will be responsible for marketing and distribution in the US.

Aspen's abbreviated new drug application for HPC was approved by the US Food and Drug Administration in August 2015, and ANI intends to commercialize HPC in the near term.

ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company’s targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.

Source: ANI Pharmceuticals